Claims for Patent: 10,385,067

Summary for Patent: 10,385,067

Title:	Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- zepin-8-olate
Abstract:	The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,- 13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-- 8-olate Form I, pharmaceutical formulations, and uses thereof for treating or prophylactically preventing an HIV infection.
Inventor(s):	Carra; Ernest A. (Foster City, CA), Chen; Irene (San Mateo, CA), Zia; Vahid (Palo Alto, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	15/624,166
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,385,067
Patent Claims:	1. A method for treating an HIV infection in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound of Formula II: ##STR00004## which is crystalline and is characterized by an x-ray powder diffraction (XRPD) pattern having peaks at about 5.5.degree., 16.1.degree., and 23.3.degree. 2-.theta..+-.0.2.degree..+-.2-.theta.. 2. The method of claim 1, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 22.1.degree., and 28.5.degree. 2-.theta..+-.0.2.degree..+-.2-.theta.. 3. The method of claim 2, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 22.5 and 19.5.degree. 2-.theta..+-.0.2.degree..+-.2-.theta.. 4. The method of claim 3, wherein the x-ray powder diffraction (XRPD) pattern of the compound of Formula II has further peaks at about 26.6.degree. and 17.9.degree. 2-.theta..+-.0.2.degree. 2-.theta.. 5. The method of claim 1, wherein the compound of Formula II is characterized by an x-ray powder diffraction (XRPD) pattern substantially as set forth in FIG. 1. 6. The method of claim 1, wherein the compound of Formula II is characterized by differential scanning calorimetry (DSC) pattern substantially as set forth in FIG. 2. 7. The method of claim 1, wherein the compound of Formula II is characterized by a dynamic vapor sorption (DVS) pattern substantially as set forth in FIG. 4. 8. The method of any one of claims 1 and 2 to 7, wherein the compound of Formula II is characterized by being partially or fully hydrated. 9. The method of any one of claims 1 and 2 to 7, wherein the compound of Formula II is characterized by being anhydrous or essentially anhydrous. 10. A method for treating an HIV infection in a human in need thereof, comprising administering to the human a pharmaceutical composition, the pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula II: ##STR00005## which is crystalline and is characterized by an x-ray powder diffraction (XRPD) pattern having peaks at about 5.5.degree., 16.1.degree., and 23.3.degree. 2-.theta..+-.0.2.degree..+-.2-.theta., and a pharmaceutically acceptable carrier or excipient. 11. The method of claim 10, wherein the pharmaceutical composition further comprises one to three additional therapeutic agents. 12. The method of claim 11, wherein the additional therapeutic agents are each anti-HIV drugs. 13. The method of claim 11, wherein the additional therapeutic agents are each independently selected from the group consisting of HIV protease inhibitors, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, pharmacokinetic enhancers, and other drugs for treating HIV. 14. The method of claim 11, wherein one of the one to three additional therapeutic agents is an HIV nucleoside inhibitor of reverse transcriptase. 15. The method of claim 10, wherein the pharmaceutical composition further comprises tenofovir disoproxil fumarate and emtricitabine. 16. The method of claim 10, wherein the pharmaceutical composition further comprises tenofovir alafenamide and emtricitabine. 17. The method of claim 10, wherein the pharmaceutical composition further comprises tenofovir alafenamide hemifumarate and emtricitabine. 18. The method of any one of claims 10 to 17, wherein the pharmaceutical composition is in a unit dosage form. 19. The method of claim 18, wherein the unit dosage form is a tablet.